Business Context and Reporting Period
Company: Surgery Partners, Inc. (SGRY)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2025
Business Overview: The Company owns and operates a national network of 165 surgical facilities (146 Ambulatory Surgery Centers and 19 surgical hospitals) across 30 states, primarily in partnership with physicians. As of the reporting date, the Company consolidated 114 facilities for financial reporting purposes.
Key Financial Metrics
| Metric (in millions) | Q3 2025 | Q3 2024 | 9M 2025 | 9M 2024 |
|---|---|---|---|---|
| Revenues | $821.5 | $770.4 | $2,423.7 | $2,249.9 |
| Operating Income | $105.7 | $60.9 | $279.3 | $221.7 |
| Net Income (Consolidated) | $25.3 | $6.4 | $69.9 | $59.1 |
| Net Loss Attributable to Surgery Partners | $(22.7) | $(31.7) | $(62.9) | $(59.6) |
| Adjusted EBITDA | $136.4 | $128.6 | $369.3 | $344.4 |
| Cash and Cash Equivalents | $203.4 | $221.8 | $203.4 | $221.8 |
| Operating Cash Flow (9M) | $170.9 | $188.7 | $170.9 | $188.7 |
| Total Debt (Gross) | $3,563.6 | $3,370.3 | $3,563.6 | $3,370.3 |
| Interest Expense, Net (9M) | $205.0 | $148.8 | $205.0 | $148.8 |
Liquidity: As of September 30, 2025, the Company had $203.4 million in cash and $405.9 million in availability under its senior secured revolving credit facility.
Material Changes vs. Prior Period
- Revenue Growth: Q3 2025 revenues increased 6.6% year-over-year, driven by a 6.3% increase in days-adjusted same-facility revenues (comprising a 3.4% increase in case volume and 2.8% increase in revenue per case) and net acquisitions.
- Profitability: Operating income improved significantly to $105.7 million in Q3 2025 from $60.9 million in Q3 2024. Adjusted EBITDA rose 6.1% to $136.4 million.
- Net Loss Attributable to Parent: While consolidated net income increased, the net loss attributable to Surgery Partners, Inc. narrowed to $22.7 million from $31.7 million in the prior year quarter. This is primarily due to higher net income attributable to non-controlling interests ($48.0 million vs. $38.1 million).
- Interest Expense: Net interest expense increased to $74.9 million in Q3 2025 from $50.0 million in Q3 2024, driven by increased borrowings on the Revolver and the maturity of interest rate swaps in Q1 2025.
- Transaction Costs: Transaction and integration costs decreased to $12.6 million in Q3 2025 from $29.4 million in Q3 2024, reflecting reduced M&A activity and integration costs.
Guidance, Outlook, and Risks
Management Commentary: Management continues to focus on same-facility performance, selective acquisitions, and portfolio management. The Company completed the acquisition of four surgical facilities and five physician practices in Q3 2025 for $52.6 million in cash consideration.
Legislative Impact: The "One Big Beautiful Bill Act" (OBBBA) passed in July 2025 introduced changes to Medicare, Medicaid, and the ACA. Management does not expect these changes to materially impact financial statements, though they may increase regulatory burdens.
Risks and Contingencies:
- Debt Refinancing: In August 2025, the Company entered a Second Amendment to its Credit Agreement, refinancing term loans and the revolver. This resulted in a $1.3 million loss on debt extinguishment.
- Interest Rate Risk: The Company utilizes interest rate swaps and caps to manage exposure. Several swaps matured in March 2025, replaced by deferred premium caps.
- Legal Proceedings: The Company is subject to ordinary course claims (professional liability, employment, etc.). Management does not believe any current proceedings will have a material adverse effect.
- Board Changes: Dr. Patricia A. Maryland, a Board member since 2021, passed away in October 2025. Dr. Laura Forese was appointed to the Nominating and Corporate Governance Committee.
Investor Verification Checklist
- Non-Controlling Interests: Verify the impact of the $48.0 million net income attributable to non-controlling interests on the reported net loss to the parent company.
- Debt Structure: Review the terms of the August 2025 Credit Agreement amendment, specifically the new interest rates (SOFR + 2.50%) and maturity dates (2030 for term loans).
- Same-Facility Growth: Confirm the sustainability of the 6.3% same-facility revenue growth and the mix of volume vs. price increases.
- Interest Rate Exposure: Assess the Company's exposure to rising interest rates following the maturity of fixed-rate swaps in Q1 2025 and the reliance on deferred premium caps.
- Acquisition Pipeline: Evaluate the $52.6 million in Q3 acquisitions and the associated goodwill recognition ($78.6 million) for potential future impairment risks.